WE COLLABORATE WITH PHARMACEUTICAL COMPANIES TO ACCELERATE PATIENT’S ACCESS TO NOVEL THERAPIES

FACTS

14 CLINICS In 8 countries in Europe,
North America and Africa
MORE...
15 TO 60 DAYS Fast start-up/regulatory
timelines
MORE...
5 TO 30-FOLD Patient enrollment
vs competition
MORE...
9 TO 24 MONTHS PROOF-OF-CONCEPT MORE...

DISRUPTIVE ADDED VALUE

UNIQUE APPROACH TO EVALUATE EFFICACY OF NOVEL THERAPEUTICS IN RECORD TIME

The pharmaceutical industry is under increased pressure to advance the development of new therapies in a fast and efficient manner, whilst ensuring the safety and quality of data.

ARENSIA’s playing field

The PROOF OF CONCEPT phase, particularly the "first-in-patient" clinical trials (Phase IB or IIA), is critical in the drug development process. It detects the initial efficacy signal of new therapies (compounds) in the targeted patient population. Data from these trials determine whether to continue or halt research of the respective new compound before significant investments in later phases of drug development.

Industry challenge

The growing demands for sophisticated Phase I/II PROOF OF CONCEPT protocols with innovative compounds in clinical trials require expert, dedicated research staff and facilities. However, typical clinical trial sites often lack dedicated personnel and expertise, forcing pharmaceutical companies to involve multiple sites to complete their trials. This results in high costs, delays, and quality issues for PROOF-OF-CONCEPT trials with relatively low patient numbers (12 to 200).

ARENSIA solution

At ARENSIA, we have addressed industry needs by establishing a proprietary network of research clinics in 8 countries over the past decade, spanning various therapeutic areas.

All ARENSIA Clinics are exclusively dedicated to expediting PROOF OF CONCEPT trials, ensuring the highest safety standards for patients and data quality.

Typical clinical trial sites encounter challenges like overcrowded schedules, insufficient staff, and prolonged contract negotiations. In contrast, ARENSIA Clinics achieve significant time reductions through unparalleled recruiting performance. By concentrating efforts on a select number of ARENSIA's research-dedicated clinics instead of a high number of clinical trial sites, we achieve a budget reduction of at least 50% for Phase IB/IIA PROOF-OF-CONCEPT trials.

Our 93% repeat business underscores that ARENSIA delivers a disruptive breakthrough in time and cost, fostering continuous growth and collaborations with leading pharmaceutical companies, biotechs, and global CROs

WATCH THIS VIDEO Find out more about us in 2 minutes

WHAT OUR SPONSORS SAID

In regards to patient enrollment, ARENSIA fulfilled their recruitment commitment and went on to enroll more patients than initially assigned. The ARENSIA Team demonstrated very high medical proficiency, trustworthiness and business sophistication.

Leading Global Pharmaceutical Company, US based

We have very much appreciated the opportunity to work with ARENSIA and together further pioneer science. Not only did you help us enroll the study in record time, you have worked diligently to help us with a successful cohort lock. We look forward to continuing our partnership.

Mid-Size Biotech Company, US based

We are extremely happy and impressed with our partnership with ARENSIA. I already said a few times in our calls with the Sponsor and my team that I have never seen such a pace and successful collaboration in my 21 years in the industry.

Leading Global CRO, US based

NEWS

FIRST CALL INNOVATIONXCHANGE BY ARENSIA IN ZURICH FIRST CALL INNOVATIONXCHANGE BY ARENSIA IN ZURICH 15.01.2024

Following a resonant success from San Francisco, we are thrilled to announce the next edition in the summit series: "RACE FOR PROOF OF CONCEPT...

READ MORE
CLINICAL TRIALS IN UKRAINE: STATUS QUO AND OPPORTUNTIES CLINICAL TRIALS IN UKRAINE: STATUS QUO AND OPPORTUNTIES 10.01.2024

🔊 FIRST CALL! LIVE WEBINAR 📈 CLINICAL TRIALS IN UKRAINE: STATUS QUO AND OPPORTUNITIES 📅 Monday, February 5, 2024 ⏰ 5:00 PM CET / 11:00 A...

READ MORE
ARENSIA WEBSITE AVAILABLE IN MANDARIN ARENSIA WEBSITE AVAILABLE IN MANDARIN 04.01.2024

The New Year starts with great news! The ARENSIA website is now available in Mandarin! This is a result of the growing interest of companies from the ...

READ MORE
ARENSIA OPENS PATIENT-CENTRIC RESEARCH CLINIC IN THE USA FOR PHASE I&II TRIALS ARENSIA OPENS PATIENT-CENTRIC RESEARCH CLINIC IN THE USA FOR PHASE I&II TRIALS 27.10.2023

We are delighted to announce the opening of ARENSIA Research Clinic in the USA, located in Phoenix, Arizona! Our mission for the clinic in the US a...

READ MORE
ARENSIA ENROLLS A COMPLEX PHASE IIA TRIAL WITH 30 ULCERATIVE COLITIS PATIENTS IN 10 MONTHS! ARENSIA ENROLLS A COMPLEX PHASE IIA TRIAL WITH 30 ULCERATIVE COLITIS PATIENTS IN 10 MONTHS! 25.10.2023

We are delighted to share one of the most recent achievements at ARENSIA! Three ARENSIA clinics in Romania, Moldova, and Georgia have just completed t...

READ MORE
INNOVATIONXCHANGE SUMMIT PLATFORM BY ARENSIA INNOVATIONXCHANGE SUMMIT PLATFORM BY ARENSIA 18.09.2023

ARENSIA is delighted to introduce its latest face-to-face summit platform: INNOVATIONXCHANGE! On November 6th, we will inaugurate our first event a...

READ MORE
ARENSIA CLINICS SPEED UP NEURO-PSYCHIATRIC TARGET EXPLORATION! ARENSIA CLINICS SPEED UP NEURO-PSYCHIATRIC TARGET EXPLORATION! 11.09.2023

Neuroscience clinical trials thrive on a diverse range of factors such as novel target identification methods, comprehensive AI integration, real-worl...

READ MORE
CONTACT US